Methods and compositions for preventing or treating calciphylaxis
AssigneeEpizon Pharma, Inc.
InventorsJames A. Tumlin, Paul L. Darke, John M. Rudey
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.
Claims36
A method of treating calciphylaxis in a human subject in need thereof, the method comprising administering to the human subject a composition comprising menaquinol-7 (MKH2-7) thereby to treat calciphylaxis in the subject,
- whereupon the administration of the MKH2-7 to the subject:
- (i) decreases a plasma level of Highly Sensitive C Reactive Protein (hs-CRP) relative to the plasma level of hs-CRP prior to administration;
- or
- (ii) increases a plasma level of osteoprotegerin relative to the plasma level of osteoprotegerin prior to administration.
A method of increasing vascular compliance in a subject in need thereof, the method comprising administering to the subject an effective amount of menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), the method comprising administering to the human subject a composition comprising MK-7 and/or MKH2-7 thereby to increase vascular compliance in the subject,
- whereupon the administration of the MK-7 and/or MKH2-7 to the subject:
- (i) increases a plasma level of Fetuin A relative to the plasma level of Fetuin A prior to administration;
- (ii) decreases a plasma level of Highly Sensitive C Reactive Protein (hs-CRP) relative to the plasma level of hs-CRP prior to administration;
- or
- (ii) increases a plasma level of osteoprotegerin relative to the plasma level of osteoprotegerin prior to administration.
Dependencies are inferred from the claim text.